ClinicalTrials.gov
ClinicalTrials.gov Menu

Heparin Induced Thrombocytopenia: Pharmacoeconomics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00456001
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : March 2, 2009
Sponsor:
Collaborator:
Sanofi
Information provided by:
Brigham and Women's Hospital

Brief Summary:

Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.

Subsequently, we will compare the heparin induced thrombocytopenia rates associated with heparin and low molecular weight heparin usage as well as evaluate the economic and long-term clinical burden of heparin induced thrombocytopenia.


Condition or disease
Heparin Induced Thrombocytopenia (HIT)

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term Clinical Burden of Heparin Induced Thrombocytopenia.
Study Start Date : July 2006
Actual Primary Completion Date : September 2008
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
Drug Information available for: Heparin




Primary Outcome Measures :
  1. Clotting and Bleeding Complications [ Time Frame: 90 Days ]

Secondary Outcome Measures :
  1. Mortality [ Time Frame: 30 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients hospitalized at BWH who have a PF4-Positive antibody test
Criteria
All patients hospitalized at BWH who have a PF4-Positive antibody test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456001


Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Sanofi
Investigators
Principal Investigator: Samuel Z. Goldhaber, MD Brigham and Women's Hospital

Additional Information:
Publications:
Responsible Party: Samuel Z. Goldhaber, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00456001     History of Changes
Other Study ID Numbers: 2006-P-001982
First Posted: April 4, 2007    Key Record Dates
Last Update Posted: March 2, 2009
Last Verified: February 2009

Keywords provided by Brigham and Women's Hospital:
heparin
low molecular weight heparin
enoxaparin
anticoagulation
thrombosis
venous thrombosis
thromboembolism
pulmonary embolism
medication

Additional relevant MeSH terms:
Thrombocytopenia
Blood Platelet Disorders
Hematologic Diseases
Calcium heparin
Heparin
Heparin, Low-Molecular-Weight
Dalteparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action